Optimising RWE to deliver value in healthcare
- 23 September 2026
- 09:00 - 14:00 CEST
-
VBO FEB - Verbond van Belgische Ondernemingen
Fédération des Entreprises de Belgique
- 23 September 2026
- 09:15 - 14:00 CEST
-
VBO FEB - Verbond van Belgische Ondernemingen
Fédération des Entreprises de Belgique
- 08:45 - 09:15
Participant arrival and registration
Welcome and opening statement
- 09:15 - 09:20
Housekeeping
Laura Batchelor, Managing Partner, FIPRA International
Karen Facey, RWE4Decisions, Senior HTA Advisor
Navigating Europe’s Future - Opportunities for RWE Innovation?
Moderated by
Hans-Georg Eichler, Consultant Physician, Association of Austrian Social Insurance Institutions
- 09:20 - 09:35
Keynote address: Implementing the EU HTA Regulation
Roisin Adams, Head of HTA Strategy, National Centre for Pharmacoeconomics, Ireland
- 09:35 - 09:45
Investing in life sciences
Kristin Thompson, Investment Director (Life Sciences), Merieux Equity Partner
- 09:45 - 10:00
Multi-stakeholder panel: The geopolitical shifts impacting the EU
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Niklas Hedberg, Chief Pharmacist, TLV
Wim van Harten, Research Group leader, Netherlands Cancer Institute
- 10:00 - 10:25
Moderated Q&A with the audience
Roisin Adams, Head of HTA Strategy National Centre for Pharmaeconomics, Ireland
The European Health Data Space
Moderated by
Eric Sutherland, Senior Health Economist, OECD
- 10:25 - 10:35
EHDS Implementation
Nienke Schutte, Head of Unit, Innovation in Health Information Systems Unit, Sciensano
- 10:35 - 10:50
Multi-stakeholder panel: Opportunities and challenges in EHDS implementation
Christian Dehlendorff, Biostatistical Chief Consultant, Danish Medicines Council
Dorota Religa , MD, PhD, Director, Swedish registry for cognitive / dementia disorders, Karolinska University Hospital, Sweden
Diana Sinkevich, VP Market Access EU & International and Global HEOR, Chiesi
- 10:50 - 11:10
Moderated Q&A with the audience
Roisin Adams, Head of HTA Strategy National Centre for Pharmaeconomics, Ireland
- 11:10 - 11:40
Break
AI for RWE Generation
Moderated by
Shaun Rowark, Associate Director Data Analytics, NICE
- 11:40 - 11:50
Scene setting: A reasonable validation framework for AI in RWE generation?
Shaun Rowark, Associate Director Data Analytics, NICE
- 11:50 - 12:00
Multi-stakeholder panel: Ensuring AI-generated RWE meets HTA, patient, and societal needs
Jing Wang-Silvanto, Member, Observational Health Data Sciences and Informatics (OHDSI)
Saunya Dover, Director Science and Methods, Canada’s Drug Agency (CDA)
Dr Tonya Winders, President and Acting CEO, Global Allergy & Airways Patient Platform (GAAPP)
- 12:00 - 12:20
Moderated Q&A with the audience
Roisin Adams, Head of HTA Strategy National Centre for Pharmaeconomics, Ireland
RWE4Decisions Priorities to Support Better RWE Generation for HTA/Payer Decision-Making
Moderated by
Karen Facey, RWE4Decisions, Senior HTA Advisor
- 12:20 - 12:30
Review of RWE4Decisions’ 2026 activities
Karen Facey, RWE4Decisions, Senior HTA Advisor
- 12:30 - 12:45
Priorities for 2027 – RWE4Decisions Steering Group
Hans-Georg Eichler, Consultant Physician, Association of Austrian Social Insurance Institutions
Ashley Jaksa, Principal for Research Partnerships, Pedestal Health
François Houÿez, Director of Treatment Information and Access, EURORDIS
Klaus Pugner, Market Access Head New Product Planning, Region Europe and Canada, Takeda
Toon Digneffe, Head EU Public Affairs International, Takeda
- 12:45 - 13:00
Closing remarks
Laura Batchelor, Managing Partner, FIPRA International
- 13:00 - 14:00